Nomogram to predict duration of clinical benefit from nivolumab in platinum resistant, recurrent/metastatic head and neck squamous cell carcinoma
Authors
Feeney, L.Rack, Samuel
Mistry, Hitesh
Bola, Becky
McPartlin, Andrew J
Sykes, Andrew J
Metcalf, Robert
Affiliation
Belfast City Hospital, Belfast, United KingdomIssue Date
2022
Metadata
Show full item recordCitation
Feeney L, Rack S, Mistry H, Bola B, McPartlin A, Sykes A, et al. Nomogram to predict duration of clinical benefit from nivolumab in platinum resistant, recurrent/metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology. 2022 Jun;40(16):E18016-E. PubMed PMID: WOS:000863680303594.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.e18016Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.e18016